India · Delayed Price · Currency is INR HealthCare Global Enterprises Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue grew 13.4% year-over-year to INR 633 crore, with adjusted EBITDA up 20% and margins expanding. Guidance remains at 15%+ annual growth, with margin and ROCE expected to rise as centers mature and new expansions come online.
Fiscal Year 2025
-
Strong revenue and EBITDA growth in FY 2025 was driven by core oncology centers, expansion, and digital initiatives. Margin improvement is expected as emerging centers mature, with over 900 new beds planned in three years and a focus on reducing debt through equity infusion.
-
Q3 FY25 saw record revenue of INR 559 crore (+19% YoY) and strong EBITDA growth, with emerging centers and recent acquisitions driving performance. KKR's majority stake marks a strategic shift, while margin expansion and robust growth are expected in the coming quarters.
-
Q2 FY25 saw record revenue and EBITDA growth, with margins expanding and digital initiatives driving patient acquisition. Expansion through acquisitions and new centers continues, while international business is expected to recover by Q4.
-
Q1 FY25 saw record revenue and EBITDA growth, driven by strong performance across centers, strategic acquisition in Vizag, and digital initiatives. EBITDA margin is expected to reach 19%-20% for established centers, with continued investment in expansion and operational efficiency.